Wuxi Biologics (Cayman) Inc revenue for the last year amounted to 2.36 B USD, the most of which — 1.89 B USD — came from its highest performing source at the moment, Research Services on Fee-for-Service, the year earlier bringing 1.25 B USD. The greatest contribution to the revenue figure was made by North America — last year it brought Wuxi Biologics (Cayman) Inc 1.26 B USD, and the year before that — 810.76 M USD.